PET/CT Molecular Imaging of Angiogenesis in Pulmonary or Head and Neck Cancers Prior to or During Chemotherapy Including Agent With Antiangiogenic Effect. A Prospective Multicentric Study of Efficacy and Tolerability.

The primary objective of this Phase II study is to evaluate the use of labelled RGD ligand in PET/CT to predict and/or to early assess the efficacy of chemotherapy including an agent with antiangiogenic effect.
The predictive value of this approach will be determined by independent assessors on basis of data at the end of the treatment: RECIST 1.1 criteria for CT or MRI, PERCIST criteria for FDG PET/CT, clinical, endoscopic and histological findings.

开始日期2015-03-20

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

100 项与 Flotegatide-F18 相关的临床结果

登录后查看更多信息

100 项与 Flotegatide-F18 相关的转化医学

登录后查看更多信息

100 项与 Flotegatide-F18 相关的专利（医药）

登录后查看更多信息

项与 Flotegatide-F18 相关的文献（医药）

2014-06-01·Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology3区 · 医学

Atherosclerotic plaque uptake of a novel integrin tracer 18F-Flotegatide in a mouse model of atherosclerosis

3区 · 医学

Article

作者: Gang Chen ; Katrin Szardenings ; Luis Felipe Gomez ; Joseph C. Walsh ; Natalia Gorodny ; Daniel S. Berman ; Fanrong Mu ; Helen Su ; Hartmuth C. Kolb ; Umesh B. Gangadharmath ; Balaji K. Tamarappoo

INTRODUCTION:

Rupture of unstable atherosclerotic plaque that leads to stroke and myocardial infarction may be induced by macrophage infiltration and neovessel formation. A tracer that selectively binds to integrin αvβ3 a protein expressed by macrophages and neovascular endothelium may identify rupture prone plaque.

METHODS:

(18)F-labeled "R-G-D" containing tripeptide (Flotegatide), a click chemistry derived radiotracer that binds to integrin αvβ3 was injected in ApoE knockout mice fed a high fat diet. Uptake of Flotegatide by atherosclerotic plaque was visualized by micro-PET, autoradiography, and correlated to histologic markers of inflammation and angiogenesis.

RESULTS:

We found that Flotegatide preferentially binds to aortic plaque in an ApoE knockout mouse model of atherosclerosis. The tracer's uptake is strongly associated with presence of histologic markers for macrophage infiltration and integrin expression. There is a weaker but detectable association between Flotegatide uptake and presence of an immunohistochemical marker for neovascularization.

DISCUSSION:

We hypothesize that Flotegatide may be a useful tracer for visualization of inflamed plaque in clinical subjects with atherosclerosis and may have potential for detecting vulnerable plaque.

100 项与 Flotegatide-F18 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
颈动脉狭窄	临床2期	美国	Siemens Molecular Imaging, Inc.	2012-05-01
乳腺癌	临床2期	美国	Siemens Molecular Imaging, Inc.	2009-09-01
结直肠癌	临床2期	美国	Siemens Molecular Imaging, Inc.	2009-09-01
非小细胞肺癌	临床2期	美国	Siemens Molecular Imaging, Inc.	2009-09-01
肿瘤	临床2期	法国	Assistance Publique des Hôpitaux de Paris SA	-
胶质瘤	临床1期	美国	Siemens Molecular Imaging, Inc.	2008-08-01
黑色素瘤	临床1期	美国	Siemens Molecular Imaging, Inc.	2008-08-01
肉瘤	临床1期	美国	Siemens Molecular Imaging, Inc.	2008-08-01
动脉粥样硬化	临床前	美国	Siemens Molecular Imaging, Inc.	-